Member Info for Dote59

Up 15% trading as TAP on AQSE

Acq of TAP approved and trading to resume tomorrow.

RNS today says dealing to recommence 10.1.23. More details of issue.

Why do these companies use placings that we cannot access instead of rights issues? HL do not have a working relationship with Peterhouse and therefore will not apply for Broker Option Shares. So we are diluted. If this were to continue could the company's major share holders end up with >50% and take this private at a low price and reap the benefits?

Edison has dropped coverage of OO and 2 other cos.

A note out dated 21st June values OO shares at 34p. I note the downgrade to 0.54p of eps from previous 0.67p to Dec 22 (not mentioned). The price is stated as 16p!! but the chart shows about 11p. They say they are valued at over twice the current share price (3 times really).

Ironman is correct; EPS is the true measure and the PE relative to future growth and the market.
EV/SALES type valuations is some of parts used for comparison (but OO is unique) and often used to gauge predator interest (unlikely until the 2 minor spin offs are done). 18.3x PE to Dec 22 is a tad high in the current market conditions with lack of future eps guidance and delay in spin offs. Mo buying shares will help. LT it still has good potential.

Agree DesertStar. They currently trade at 18.9x PE to Dec 2022 based on the highest forecast I have seen.

It appears to be Croft's fault. They are presumably dematerialising each holding broker by broker with HL clients last.

The slowness of getting the historic results out (usually Dec year end out by March) is holding back the price, as is the lack of sell-off news. Both would be confirmation of value.
Once the results are out, hopefully we will be steered towards better broker forecasts for YE2022 and more about the contracts and prospects for 2023.

The SP is likely to be held down by the MMs until they know all shares are tradeable and the spivs have finished selling. That will be the bottom and serious investors that have not found enough stock, as well as hopefully JS, will push the price up to a more sensible level IMO.

HL claim that they never received notification on the offer at 5.9p. Still no sign of our holdings from Croft! 20 days after the lock-in ending.

Thompi - HL claim that they have had no direct contact from Poolbeg. I have asked Poolbeg why not?

I have not even received a letter via HL, not that I am interested in selling. Indeed it is a raging by if one assumes polb 001 will be sold to big pharma sometime around year end.

They are PE 19X Dec 2022 eps - expensive in a bear market. The results in March hopefully will lead to an upgrade and comment on the outlook for 2023, as well as the disposals/floats that are well overdue.

The 2021PE should of course have been 825X! Not 33X. Hopefully we will get some guidance on 2023 revenues to justify a greater valuation. CF said that DIM spin off/sale would wait for Poolbeg to be sorted. The target for Poolbeg I took as March 2022 because why else prevent sales. They were hoping for a price rise on additions to portfolio followed by US listing, but it now looks like Poolbeg is all about the end of year. I think only news of spin offs/sales on good terms will drive the SP up now. More may be said when the results come out.

Correction 2022PE is 24.5X.

Proactive research today values OO at 34p + 3 unvalued assets (spin offs/sales and Poolbeg already delivered 4p). But more interesting to me is 2021PE 33X and 2022PE 11X at 16.5p. Obviously, small companies have fallen due to the usual derisking by "investors" when interest rates are rising (and potential war in the background).

Does anyone know if the LSE "Short Positions" tab actually works?

GG when you say "a forward PE of more than 12", OO core is on a PE of 40 for 2022 based on finnCap's forecast.